Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00JAU
|
||||
Former ID |
DAP000364
|
||||
Drug Name |
Irbesartan
|
||||
Synonyms |
Aprovel; Avapro; Irbesarran; Irbetan; Karvea; Lrbesartan; BMS Brand of Irbesartan; Bristol Myers Brand of Irbesartan; SanofiWinthrop Brand of Irbesartan; BMS 186295; SR 47436; Aprovel (TN); Avalide (TN); Avapro (TN); BMS-186295; Irbesartan [USAN:INN]; Karvea (TN); SR-47436; Irbesartan (JAN/USAN/INN); BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one; 2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antihypertensive Agents
|
||||
Company |
Bristol-Myers Squibb
|
||||
Structure |
Download2D MOL |
||||
Formula |
C25H28N6O
|
||||
InChI |
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
|
||||
InChIKey |
YOSHYTLCDANDAN-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 138402-11-6
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9672, 5243560, 7847589, 8152372, 11364645, 11367207, 11369769, 11372006, 11374741, 11377931, 11485625, 11489491, 11490809, 11492936, 11495565, 11528645, 12014641, 14758693, 14905264, 26612692, 26680708, 26719813, 26748950, 26748951, 29222869, 46386566, 46506575, 46530573, 47365300, 48035232, 48416128, 49681744, 49830881, 50107493, 53787775, 56312044, 56313979, 57321974, 77118987, 81092816, 85174437, 85209120, 85789259, 91011661, 92124749, 92307926, 92308458, 92713301, 93166505, 93621098
|
||||
ChEBI ID |
ChEBI:5959
|
||||
SuperDrug ATC ID |
C09CA04
|
||||
SuperDrug CAS ID |
cas=138402116
|
||||
Target and Pathway | |||||
Target(s) | Type-1 angiotensin II receptor | Target Info | Antagonist | [537449] | |
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
Pathway Interaction Database | Arf6 trafficking events | ||||
Arf6 signaling events | |||||
Angiopoietin receptor Tie2-mediated signaling | |||||
PathWhiz Pathway | Angiotensin Metabolism | ||||
Muscle/Heart Contraction | |||||
References | |||||
Ref 536095 | New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. | ||||
Ref 541187 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 589). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.